Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
The identification of succinate dehydrogenase (SDH), fumarate hydratase (FH) and isocitrate dehydrogenase (IDH) mutations in human cancers has rekindled the idea that altered cellular metabolism can transform cells. Inactivating SDH and FH mutations cause the accumulation of succinate and fumarate, respectively, which can inhibit 2-oxoglutarate (2-OG)-dependent enzymes, including the EGLN prolyl 4-hydroxylases that mark the hypoxia inducible factor (HIF) transcription factor for polyubiquitylation and proteasomal degradation. Inappropriate HIF activation is suspected of contributing to the pathogenesis of SDH-defective and FH-defective tumours but can suppress tumour growth in some other contexts. IDH1 and IDH2, which catalyse the interconversion of isocitrate and 2-OG, are frequently mutated in human brain tumours and leukaemias. The resulting mutants have the neomorphic ability to convert 2-OG to the (R)-enantiomer of 2-hydroxyglutarate ((R)-2HG). Here we show that (R)-2HG, but not (S)-2HG, stimulates EGLN activity, leading to diminished HIF levels, which enhances the proliferation and soft agar growth of human astrocytes. These findings define an enantiomer-specific mechanism by which the (R)-2HG that accumulates in IDH mutant brain tumours promotes transformation and provide a justification for exploring EGLN inhibition as a potential treatment strategy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Insulator dysfunction may also be accompanied by promoter silencing events28,29, and by alterations to other pathways affected by 2-HG7,30.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [30]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“(R)-2HG competitively inhibited BCAT1, which is a cytosolic enzyme, with respect to 2OG over a physiologically-relevant range of 2OG concentrations”
From Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma (2018) · cites this paper as Koivunen et al., 2012
Experimental — accuracy not yet measuredIn the citing paper
“Though it is found at low levels in normal cells, D-2HG can accumulate to millimolar levels in cancer cells expressing mutant IDH. At these high concentrations, D-2HG can inhibit αKG-dependent dioxygenases, including enzymes involved in histone and DNA demethylation (Chowdhury et al., 2011; Janke et al., 2017; Koivunen et al., 2012; Xu et al., 2011).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Koivunen et al., 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
Self-citationCancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875 · cited 1×
“Consistent with recent reports, we found that both ( R )-2HG and ( S )-2HG inhibit a number of 2-OG-dependent enzymes in vitro”
BackgroundFigueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766 · cited 1×
“Consistent with recent reports, we found that both ( R )-2HG and ( S )-2HG inhibit a number of 2-OG-dependent enzymes in vitro”
BackgroundRole of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998) · Nature · doi:10.1038/28867 · Cited by 2,502 · cited 1×
“Although HIF is typically viewed as an oncoprotein it can behave as a tumour suppressor in embryonic stem cell”
BackgroundHypoxia-inducible factors and the response to hypoxic stress
Majmundar, A. J., Wong, W. J., & Simon, M. C. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.022 · Cited by 2,380 · cited 1×
“Inactivating SDH and FH mutations cause the accumulation of succinate and fumarate, respectively, which can inhibit 2-oxoglutarate (2-OG)-dependent enzymes, including the EGLN prolyl 4-hydroxylases that mark the hypoxia inducible factor (HIF) transcription factor for polyubiquitylation and proteasomal degradatio”
BackgroundIto, S., D’Alessio, A. C., Taranova, O. V., Hong, K., Sowers, L. C., & Zhang, Y. (2010) · Nature · doi:10.1038/nature09303 · Cited by 2,373 · cited 1×
“Human EGLN1, 2 and 3, collagen P4H-I and FIH, and murine Tet1 and Tet2 were produced in insect cells and purified as described earlie”
MethodAbsolute metabolite concentrations and implied enzyme active site occupancy in Escherichia coli
Bennett, B. D., Kimball, E. H., Gao, M., Osterhout, R., Van Dien, S. J., & Rabinowitz, J. D. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.186 · Cited by 1,830 · cited 1×
“Studies in model organisms suggest that many metabolic enzymes are saturated in vivo with a mixture of substrate and competitive inhibitors and thus are sensitive to changes in substrate concentrations that are far above their nominal K m value”
BackgroundGlioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
Zhao, S., Lin, Y., Xu, W., Jiang, W., Zha, Z., Wang, P., Yu, W., Li, Z., Gong, L., Peng, Y., et al. (2009) · Science · doi:10.1126/science.1170944 · Cited by 1,119 · cited 1×
“Nor are our data incompatible with the finding that HIF-1a protein levels are increased in IDH mutant tumours relative to normal brai”
ResultThe oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases
Chowdhury, R., Yeoh, K. K., Tian, Y., Hillringhaus, L., Bagg, E. A., Rose, N. R., Leung, I. K. H., Li, X. S., Woon, E. C. Y., Yang, M., et al. (2011) · The EMBO Reports · doi:10.1038/embor.2011.43 · Cited by 1,035
Cited by
Items 301–400 of 752
Roles of IDH1/2 and TET2 mutations in myeloid disorders
Inoue, S., Lemonnier, F., & Mak, T. W. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-1973-7 · Cited by 57
Elevated d -2-hydroxyglutarate during colitis drives progression to colorectal cancer
Han, J., Jackson, D. N., Holm, J., Turner, K., Ashcraft, P., Wang, X., Cook, B. N., Arning, E., Genta, R. M., Venuprasad, K., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1712625115 · Cited by 52
“Of these, 2HG, specifically the enantiomer D2HG, has an emerging role in oncogenesis (14, 15).”
BackgroundWomeldorff, M. R., Gillespie, D. L., & Jensen, R. L. (2014) · Neurosurgical FOCUS · doi:10.3171/2014.9.focus14496 · Cited by 52
Glutamate as chemotactic fuel for diffuse glioma cells: Are they glutamate suckers?
van Lith, S. A. M., Navis, A. C., Verrijp, K. N., Niclou, S. P., Bjerkvig, R., Wesseling, P., Tops, B. B. J., Molenaar, R. J., Noorden, C. J. F. V., & Leenders, W. P. J. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.04.004 · Cited by 56
Epimetabolites: discovering metabolism beyond building and burning
Showalter, M. R., Čajka, T., & Fiehn, O. (2017) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2017.01.012 · Cited by 52
Yao, J., Chakhoyan, A., Nathanson, D. A., Yong, W. H., Salamon, N., Raymond, C., Mareninov, S., Lai, A., Nghiemphu, P. L., Prins, R. M., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz078 · Cited by 51
Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate
Chaturvedi, A., Cruz, M. M. A., Jyotsana, N., Sharma, A., Goparaju, R., Schwarzer, A., Görlich, K., Schottmann, R., Struys, E. A., Jansen, E. E. W., et al. (2016) · Leukemia · doi:10.1038/leu.2016.71 · Cited by 53
Uckermann, O., Yao, W., Juratli, T. A., Galli, R., Leipnitz, E., Meinhardt, M., Koch, E., Schackert, G., Steiner, G. R., & Kirsch, M. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2883-8 · Cited by 52
IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical Implications
Choate, K. A., Pratt, E. P. S., Jennings, M. J., Winn, R. J., & Mann, P. B. (2024) · Biology · doi:10.3390/biology13110885 · Cited by 61
“PHDs utilize α KG as a substrate to selectively hydroxylate targets and are susceptible to dysregulation by the accumulation of D-2-HG [69].”
Hypoxia and Metabolism in Cancer
Bensaad, K., & Harris, A. L. (2013) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-5915-6_1 · Cited by 53
DNA Modifications and Neurological Disorders
Weng, Y., An, R., Shin, J., Song, H., & Ming, G. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0223-4 · Cited by 55
Rates and Patterns of Clonal Oncogenic Mutations in the Normal Human Brain
Ganz, J., Maury, E. A., Becerra, B., Bizzotto, S., Doan, R. N., Kenny, C. J., Shin, T., Kim, J., Zhou, Z., Ligon, K. L., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0245 · Cited by 48
“Because heterozygous IDH1 mutations confer a proliferative advantage in human astrocytes and remodel chromatin into a neural progenitor-like state (34, 35), the sharply different VAFs of this mutation are most consistent with a clonal event with enhanced proliferation, present in a ≈ 5-mm 3 sample…”
Self-citationRoles of the hypoxia response system in hematopoietic and leukemic stem cells
Takubo, K., & Suda, T. (2012) · International Journal of Hematology · doi:10.1007/s12185-012-1071-4 · Cited by 50
Epigenetic changes: a common theme in acute myelogenous leukemogenesis
Gutierrez, S. E., & Romero-Oliva, F. A. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-57 · Cited by 52
“More recently, two reports found that the (R)-enantiomer of 2-HG ((R)-2HG) may actually serve as a cofactor for the activation of the Egl-Nine (EGLN) family of prolyl hydroxylases (EGLN1–3) [61,62].”
BackgroundViswanath, P., Radoul, M., Izquierdo-García, J. L., Luchman, H. A., Cairncross, J. G., Pieper, R. O., Phillips, J. J., & Ronen, S. M. (2018) · Cancer & Metabolism · doi:10.1186/s40170-018-0178-3 · Cited by 48
“However, other studies have reported unchanged or lower HIF-1α levels in IDHmut gliomas relative to IDHwt [48, 49].”
ResultLinninger, A. A., Hartung, G. A., Liu, B. P., Mirkov, S., Tangen, K. M., Lukas, R. V., Unruh, D. J., James, C. D., Sarkaria, J. N., & Horbinski, C. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy051 · Cited by 49
Rakheja, D., Medeiros, L. J., Bevan, S., & Chen, W. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00169 · Cited by 52
“…and IDH2 in combination with microenvironmental effects in certain tumor types are likely the driver mutations that are responsible for the malignant phenotype, rather than simply epiphenomena (Dang et al., 2009; Figueroa et al., 2010; Xu et al., 2011; Koivunen et al., 2012; Losman et al., 2013).”
BackgroundElevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma
Fathi, A. T., Nahed, B. V., Wander, S. A., Iafrate, A. J., Borger, D. R., Hu, R., Thabet, A., Cahill, D. P., Perry, A. M., Joseph, C. P., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0342 · Cited by 49
Ali, S. M., Yao, M., Yao, J., Wang, J., Cheng, Y., Schrock, A. B., Chirn, G., Chen, H., Mu, S., Gay, L. M., et al. (2017) · Cancer · doi:10.1002/cncr.30781 · Cited by 50
“Age, median (range), y 58 (18-80) 56 (8-87) 51 (14-90) 53 (8-90) .”
Enasidenib for the treatment of acute myeloid leukemia
Dugan, J. P., & Pollyea, D. A. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1477585 · Cited by 50
Hypoxia-Inducible Factor Prolyl 4-Hydroxylases and Metabolism
Koivunen, P., & Kietzmann, T. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.10.004 · Cited by 48
Self-citationBhavya, B., Reghuvaran, A. C., Madhusoodanan, U. K., Rajalakshmi, P., Krishnakumar, K., Easwer, H. V., Deepti, A. N., & Gopala, S. (2019) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-019-00730-3 · Cited by 48
The PLOD2/succinate axis regulates the epithelial–mesenchymal plasticity and cancer cell stemness
Tong, Y., Qi, Y., Xiong, G., Li, J., Scott, T. L., Chen, J., He, D., Li, L., Wang, C., Lane, A. N., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2214942120 · Cited by 47
Hydroxylase-dependent regulation of the NF-κB pathway
Scholz, C. C., & Taylor, C. T. (2013) · Biological Chemistry · doi:10.1515/hsz-2012-0338 · Cited by 48
IDH mutations in liver cell plasticity and biliary cancer
Saha, S. K., Parachoniak, C. A., & Bardeesy, N. M. (2014) · Cell Cycle · doi:10.4161/15384101.2014.965054 · Cited by 48
Tarhonskaya, H., Nowak, R. P., Johansson, C., Szykowska, A., Tumber, A., Hancock, R. L., Lang, P. A., Flashman, E., Oppermann, U. C. T., Schofield, C. J., et al. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.08.007 · Cited by 47
“025([28]) NR NR 13200±1100([28]) 142±30([28]) 470([45]) ABH2 2([28]) 424±77([28]) 150±20([28]) 10([28]) TET1 NR 540±100([22]) 390±160([22]) 4000([26]) 1000([26]) 55±20([22]) TET2 NR 570±190([22]) 400±70([22]) 5000([26]) 1600([26]) 60±15([22]) KDM5B 0.”
BackgroundMadala, H. R., Punganuru, S. R., Arutla, V., Misra, S., Thomas, T., & Srivenugopal, K. S. (2018) · Cancers · doi:10.3390/cancers10020049 · Cited by 50
“HIF 1α was shown to be upregulated in IDH mutant cells or cells treated with exogenous D-2HG or in Nestin-Cre mice bearing brain tumors with IDH R132H mutations [12,36,91].”
BackgroundAlberghina, L., Gaglio, D., Gelfi, C., Moresco, R. M., Mauri, G., Bertolazzi, P., Messa, C., Gilardi, M. C., Chiaradonna, F., & Vanoni, M. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00362 · Cited by 51
“In other cancer cells—including the K-ras transformed fibroblasts described herein—glutamine alone is unable to sustain growth and glucose deprivation induces cell death.”
BackgroundMolecular markers of paragangliomas/pheochromocytomas
Zhikrivetskaya, S. O., Snezhkina, A. V., Zaretsky, A. R., Alekseev, B. Y., Pokrovsky, A. V., Golovyuk, A. L., Melnikova, N. V., Stepanov, O. A., Kalinin, D. V., Moskalev, A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15201 · Cited by 45
“Subsequently, however, it was shown that 2-hydroxyglutarate was able to inhibit some 2-oxoglutarate-dependent dioxygenases although not PHD [132].”
BackgroundImpact of CDKN2A/B Homozygous Deletion on the Prognosis and Biology of IDH-Mutant Glioma
Huang, L. E. (2022) · Biomedicines · doi:10.3390/biomedicines10020246 · Cited by 51
Joberty, G., Böesche, M., Brown, J. A., Eberhard, D., Garton, N. S., Humphreys, P. G., Mathieson, T., Muelbaier, M., Ramsden, N. G., Reader, V., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00080 · Cited by 45
Targeting metabolic pathways for head and neck cancers therapeutics
Yamamoto, M., Inohara, H., & Nakagawa, T. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9691-z · Cited by 45
Zhou, Z., Ibekwe, E., & Chornenkyy, Y. (2018) · Antioxidants · doi:10.3390/antiox7010016 · Cited by 45
“However, there have been contradictory results as to the effect of 2HG on PDH and induction of a pseudohypoxic state [97].”
BackgroundUnruh, D. J., Mirkov, S., Wray, B. D., Drumm, M. R., Lamano, J. B., Li, Y. D., Haider, Q. F., Javier, R., McCortney, K., Saratsis, A. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1222 · Cited by 48
Raman Spectroscopy and Machine Learning for IDH Genotyping of Unprocessed Glioma Biopsies
Sciortino, T., Secoli, R., d’Amico, E., Moccia, S., Nibali, M. C., Gay, L. G., Rossi, M., Pecco, N., Castellano, A., Momi, E. D., et al. (2021) · Cancers · doi:10.3390/cancers13164196 · Cited by 44
“This alteration can increase the risk of DNA damage and mutation due to a rise in cellular oxidative stress [30].”
Background2-hydroxyglutarate inhibits MyoD-mediated differentiation by preventing H3K9 demethylation
Schvartzman, J. M., Reuter, V. P., Koche, R. P., & Thompson, C. B. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1817662116 · Cited by 45
Yao, J., Hagiwara, A., Raymond, C., Shabani, S., Pope, W. B., Salamon, N., Lai, A., Ji, M., Nghiemphu, P. L., Liau, L. M., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-68733-5 · Cited by 43
Characteristics of gliomas in patients with somatic IDH mosaicism
Bonnet, C., Thomas, L., Psimaras, D., Bielle, F., Vauléon, É., Loiseau, H., Cartalat‐Carel, S., Meyronet, D., Dehais, C., Honnorat, J., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0302-y · Cited by 44
“2-HG competitively inhibits multiple alpha-ketoglutarate enzymes leading to histone and DNA hypermethylation, altered cell differentiation, activation of enzymes implicated in HIF degradation and PDGFRA overexpression [14, 26, 30, 47].”
BackgroundPoinsignon, V., Mercier, L., Nakabayashi, K., David, M. D., Lalli, A., Penard‐Lacronique, V., Quivoron, C., Saada, V., de Botton, S., Broutin, S., et al. (2016) · Journal of Chromatography B · doi:10.1016/j.jchromb.2016.04.030 · Cited by 45
Mutant IDH1 Disrupts the Mouse Subventricular Zone and Alters Brain Tumor Progression
Pirozzi, C. J., Carpenter, A. B., Waitkus, M. S., Wang, C. Y., Zhu, H., Hansen, L. J., Chen, L. H., Greer, P. K., Feng, J., Wang, Y., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0485 · Cited by 44
“Mutant IDH1's effects on cellular behavior are cell context– dependent, reducing proliferation in some cases, and increasing proliferation and promoting tumorigenesis in other cases (42, 43).”
BackgroundSelf-citationGerometabolites: The pseudohypoxic aging side of cancer oncometabolites
MENENDEZ MENENDEZ, J., ALARCÓN, T., & Joven, J. (2014) · Cell Cycle · doi:10.4161/cc.28079 · Cited by 40
Ma, S., Sun, R., Jiang, B., Gao, J., Deng, W., Liu, P., He, R., Cui, J., Ji, M., Yi, W., et al. (2017) · Molecular and Cellular Biology · doi:10.1128/mcb.00492-16 · Cited by 40
Targeting fuel pocket of cancer cell metabolism: A focus on glutaminolysis
Sharma, S., Agnihotri, N., & Kumar, S. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.114943 · Cited by 45
Metabolic Roles of HIF1, c-Myc, and p53 in Glioma Cells
Trejo‐Solís, C., Castillo‐Rodríguez, R. A., Serrano-García, N., Silva‐Adaya, D., Vargas-Cruz, S., Chávez-Cortéz, E. G., Gallardo‐Pérez, J. C., Zavala-Vega, S., Cruz-Salgado, A., & Magaña-Maldonado, R. (2024) · Metabolites · doi:10.3390/metabo14050249 · Cited by 42
“2-HG stimulates PHD activity, leading to HIF1 α degradation [256], which can prevent the glycolytic switch and decrease the elevated rate of cell proliferation typical of high-grade gliomas [255].”
BackgroundBailey, P. S. J., & Nathan, J. A. (2018) · Biomedicines · doi:10.3390/biomedicines6020060 · Cited by 41
Gulaia, V. S., Kumeiko, V. V., Shved, N. A., Cicinskas, E., Александрович, Р. С., Ruzov, A. S., & Kagansky, A. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00388 · Cited by 42
“, 2011), however the most recent report states otherwise (Koivunen et al., 2012).”
BackgroundHarrelson, J. P., & Lee, M. W. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.07.014 · Cited by 42
Hypoxia-inducible factor 2α: a novel target in gliomas
Renfrow, J. J., Soike, M. H., Debinski, W., Ramkissoon, S. H., Mott, R. T., Frenkel, M. B., Sarkaria, J. N., Lesser, G. J., & Strowd, R. E. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0163 · Cited by 40
Self-citationKarsy, M. J., Guan, J., Jensen, R. L., Huang, E. L., & Colman, H. (2015) · World Neurosurgery · doi:10.1016/j.wneu.2015.12.032 · Cited by 43
Cancer metabolism as a central driving force of glioma pathogenesis
Masui, K., Cavenee, W. K., & Mischel, P. S. (2016) · Brain Tumor Pathology · doi:10.1007/s10014-016-0265-5 · Cited by 43
“production of 2-HG stimulates the activity of egl-9 family hypoxia-inducible factor (EGLN) prolyl 4-hydroxylases, which leads to reduced levels of hypoxia-inducible factor (HIF) and enhanced proliferation of human astrocytes [21].”
Reductive carboxylation and 2-hydroxyglutarate formation by wild-type IDH2 in breast carcinoma cells
Smolková, K., Dvořák, A., Zelenka, J., Vítek, L., & Ježek, P. (2015) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2015.05.012 · Cited by 40
“2HG was also reported to diminish hypoxia-induced factor (HIF) levels by stimulating EGLN prolyl-4-hydroxylase activity (Koivunen et al., 2012).”
BackgroundFilipp, F. V. (2017) · Briefings in Functional Genomics · doi:10.1093/bfgp/elx001 · Cited by 41
TET proteins in cancer: Current ‘state of the art’
Rawłuszko-Wieczorek, A. A., Siera, A., & Jagodziński, P. P. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.07.008 · Cited by 44
Mann, B., Artz, N., Darawsheh, R., Kram, D. E., Hingtgen, S., & Satterlee, A. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00832-w · Cited by 44
Nitric oxide-driven modifications of lipoic arm inhibit α-ketoacid dehydrogenases
Seim, G. L., John, S. V., Arp, N. L., Fang, Z., Pagliarini, D. J., & Fan, J. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-01153-w · Cited by 40
The mechanisms of IDH mutations in tumorigenesis
Ye, D., Xiong, Y., & Guan, K. (2012) · Cell Research · doi:10.1038/cr.2012.51 · Cited by 40
Lactate Dehydrogenase C Produces S-2-Hydroxyglutarate in Mouse Testis
Teng, X., Emmett, M. J., Lazar, M. A., Goldberg, E., & Rabinowitz, J. D. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00290 · Cited by 40
Biological Significance of Mutant Isocitrate Dehydrogenase 1 and 2 in Gliomagenesis
Ohba, S., & Hirose, Y. (2016) · Neurologia medico-chirurgica · doi:10.2176/nmc.ra.2015-0322 · Cited by 42
Identification of a Prognostic Hypoxia-Associated Gene Set in IDH-Mutant Glioma
Trong, P. D., Roesch, S., Mairbäurl, H., Pusch, S., Unterberg, A. W., Herold‐Mende, C. C., & Warta, R. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102903 · Cited by 42
From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas
Sun, X., & Turcan, Ş. (2021) · Cells · doi:10.3390/cells10051225 · Cited by 38
The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancer
Liu, Y., Xu, W., Li, M., Yang, Y., Sun, D., Chen, L., Li, H., & Chen, L. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.12.019 · Cited by 44
Targeting cancer's metabolic co-dependencies: A landscape shaped by genotype and tissue context
Bi, J., Wu, S., Zhang, W., & Mischel, P. S. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.05.002 · Cited by 37
Alhassen, S., Chen, S., Alhassen, L., Phan, A., Khoudari, M., Silva, A. D., Barhoosh, H., Wang, Z., Parrocha, C. M. T., Shapiro, E., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02255-2 · Cited by 44
Saito, Y., Ishii, K., Aita, Y., Ikeda, T., Kawakami, Y., Shimano, H., Hara, H., & Takekoshi, K. (2015) · Neurochemical Research · doi:10.1007/s11064-015-1738-3 · Cited by 39
“Thus, HIF1a and related molecules may represent potential therapeutic targets in pseudo-hypoxic–driven pheochromocytomas [43].”
BackgroundUntuning the tumor metabolic machine: HIF-α: pro- and antitumorigenic?
Young, R. M., & Simon, M. C. (2012) · Nature Medicine · doi:10.1038/nm.2865 · Cited by 37
The hypoxia signalling pathway in haematological malignancies
Irigoyen, M., García‐Ruiz, J. C., & Berra, E. (2017) · Oncotarget · doi:10.18632/oncotarget.15981 · Cited by 39
Gerecke, C., Schumacher, F., Berndzen, A., Homann, T., & Kleuser, B. (2019) · Epigenetics · doi:10.1080/15592294.2019.1666652 · Cited by 37
“[30] Koivunen P, Lee S, Duncan CG, et al.”
BackgroundOmics Integration for Mitochondria Systems Biology
Hu, X. Y., Go, Y., & Jones, D. P. (2019) · Antioxidants and Redox Signaling · doi:10.1089/ars.2019.8006 · Cited by 39
“Two key regulators of HIF-1, EglNine (EGLN, also called PHD) prolyl hydroxylase and HIF1AN (hypoxia-inducible factor 1, alpha subunit inhibitor; also called FIH) use the TCA cycle intermediates a-KG as a co-substrate to catalyze Fe(II)-dependent hydroxylation, which can be inhibited by succinate, fumarate, and 2-HG (9…”
BackgroundThe Role of Ten-Eleven Translocation Proteins in Inflammation
Gerecke, C., Rodrigues, C. E., Homann, T., & Kleuser, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.861351 · Cited by 38
Hua, L., Wang, D., Wang, K., Wang, Y., Gu, J., Zhang, Q., You, Q., & Wang, L. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00881 · Cited by 37
Evolving Treatment Strategies for Elderly Leukemia Patients with IDH Mutations
Buege, M. J., DiPippo, A. J., & Dinardo, C. D. (2018) · Cancers · doi:10.3390/cancers10060187 · Cited by 35
Predictive biomarkers in adult gliomas
Thomas, L., Stefano, A. L. D., & Ducray, F. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000002 · Cited by 35
Molecular and Genomic Landscape of Peripheral T-Cell Lymphoma
Iqbal, J., Amador, C., McKeithan, T. W., & Chan, W. C. (2018) · Cancer treatment and research · doi:10.1007/978-3-319-99716-2_2 · Cited by 39
Vohwinkel, C. U., Coit, E. J., Burns, N., Elajaili, H. B., Hernández-Saavedra, D., Yuan, X., Eckle, T. D. L. G., Nozik‐Grayck, E., Tuder, R. M., & Eltzschig, H. K. (2021) · The FASEB Journal · doi:10.1096/fj.202002778r · Cited by 35
2-Hydroxyglutarate in Acute Myeloid Leukemia: A Journey from Pathogenesis to Therapies
Raimondi, V., Ciotti, G., Gottardi, M., & Ciccarese, F. (2022) · Biomedicines · doi:10.3390/biomedicines10061359 · Cited by 38
“2-HG can activate the HIF-1α-specific prolyl hydroxylases (PDH/EGLN), which in turn promotes recognition of HIF-1α by von Hippel–Lindau (VHL) E3 ligase and its consequent proteasomal degradation [39,52,53].”
BackgroundConcise Review: Genetic Dissection of Hypoxia Signaling Pathways in Normal and Leukemic Stem Cells
Gezer, D., Vukovic, M., Soga, T., Pollard, P. J., & Kranc, K. R. (2014) · Stem Cells · doi:10.1002/stem.1657 · Cited by 37
Ratcliffe, P. J., Koivunen, P., Myllyharju, J., Ragoussis, J., Bovée, J. V. M. G., Batinic̈‐Haberle, I., Vinatier, C. S., Trichet, V., Robriquet, F., Oliver, L., et al. (2017) · Hypoxia · doi:10.2147/hp.s127042 · Cited by 36
“Regarding the effect of D2HG on prolyl hydroxylase and HIF pathway, mutations in IDH were first shown to associate with stabilization of HIF-1α,(59) but later it was shown that D2HG produced by these mutations is not a potent PHD inhibitor.(60,61) An inhibitory effect of D2HG has been demonstrated on the dioxygenase t…”
BackgroundSelf-citationHypoxic adaptation of mitochondria and its impact on tumor cell function
Benej, M., Papandreou, I., & Denko, N. C. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.03.004 · Cited by 37
Amino acid metabolism in glioblastoma pathogenesis, immune evasion, and treatment resistance
Srivastava, S., Anbiaee, R., Houshyari, M., Laxmi, L., Sridhar, S. B., Ashique, S., Hussain, M. S., Kumar, S., Taj, T., Akbarnejad, Z., et al. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03721-1 · Cited by 35
“In addition, the produced 2-HG reduces the tumor pathogenesis by downregulating HIF-1 expression [23] and improves immune response by epigenetically silencing PD-L1 (programmed cell death ligand 1) expression on cancer cells [24].”
Zhang, G., Yang, P., Guo, P.-D., Miele, L., Sarkar, F. H., Wang, Z. P., & Zhou, Q. (2013) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.03.001 · Cited by 36
Integration of hypoxic HIF-α signaling in blood cancers
Schito, L., Rey, S., & Konopleva, M. Y. (2017) · Oncogene · doi:10.1038/onc.2017.119 · Cited by 39
The PHD1 oxygen sensor in health and disease
Kennel, K. B., Burmeister, J., Schneider, M. A., & Taylor, C. T. (2018) · The Journal of Physiology · doi:10.1113/jp275327 · Cited by 36
“HIF activity, while R-2-hydroxyglutarate’s enantiomer, S-2-hydroxyglutarate, rather than R-2-hydroxyglutarate exerted inhibitory effects on PHD enzyme function (Koivunen et al. 2012; Losman et al. 2013).”
BackgroundTargeting Immunometabolism in Glioblastoma
Mohan, A. A., Tomaszewski, W. H., Haskell-Mendoza, A. P., Hotchkiss, K. M., Singh, K., Reedy, J. L., Fecci, P. E., Sampson, J. H., & Khasraw, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.696402 · Cited by 35
“demonstrated that TET2, in particular, was inhibited by 2HG (85).”
BackgroundNiu, N., Ye, J., Hu, Z., Zhang, J., & Wang, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087076 · Cited by 37
Jiang, B., Zhang, J., Xia, J., Zhao, W., Wu, Y., Shi, M., Luo, L., Zhou, H., Chen, A., Ma, H., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.03.053 · Cited by 33
Yang, S., Tan, H.-X., Lai, Z., Peng, H., Yang, H., Fu, Q., Wang, H., Li, D., & Li, M. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04639-x · Cited by 33
“Some metabolites including α-KG can serve as substrates for enzymes that modify chromatin and nucleic acids, and others such as 2-hydroxyglutarate can modify enzyme activity often by competitively inhibiting substrate utilization [37, 38].”
BackgroundWang, X., Peng, H., Yang, L., You, F., Teng, F., Hou, L., & Wolfbeis, O. S. (2014) · Angewandte Chemie · doi:10.1002/ange.201405048 · Cited by 33
Interpreting new molecular genetics in myelodysplastic syndromes
Abdel-Wahab, O. I., & Figueroa, M. E. (2012) · Hematology · doi:10.1182/asheducation.v2012.1.56.3798194 · Cited by 37
Grading of IDH-mutant astrocytoma using diffusion, susceptibility and perfusion-weighted imaging
Yang, X., Xing, Z., She, D., Lin, Y., Zhang, H., Su, Y., & Cao, D. (2022) · BMC Medical Imaging · doi:10.1186/s12880-022-00832-3 · Cited by 34
“It has been shown that IDH mutation leads to 2-HG accumulation, which may decreased hypoxiainducible-factor-1 activation and inhibited angiogenesis-related signaling [27, 28].”
BackgroundPopov, S., Jury, A., Laxton, R. C., Doey, L. J., Kandasamy, N., Al‐Sarraj, S., Jürgensmeier, J. M., & Jones, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056328 · Cited by 33
“IDH1 mutation itself may not be sufficient to account for a general HIF-1a-driven hypoxia in glioblastoma, as elevated HIF-1a levels are usually confined to severely hypoxic areas of necrosis [22] such as palisades.”
BackgroundInfluentialHypoxia-inducible factor prolyl 4-hydroxylase inhibition in cardiometabolic diseases
Koivunen, P., Serpi, R., & Dimova, E. Y. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.11.003 · Cited by 36
Self-citationA pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML
Kats, L. M., Vervoort, S. J., Cole, R., Rogers, A. J., Gregory, G. P., Vidacs, E., Li, J., Nagaraja, R., Yen, K. E., & Johnstone, R. W. (2017) · Leukemia · doi:10.1038/leu.2017.84 · Cited by 32
Rapid diagnosis of IDH1-mutated gliomas by 2-HG detection with gas chromatography mass spectrometry
Xu, H., Xia, Y., Li, C., Zhang, J., Liu, Y., Wei, Y., Qin, Z., Chen, L., Shi, Z., Quan, K., et al. (2018) · Laboratory Investigation · doi:10.1038/s41374-018-0163-z · Cited by 32
Kang, H. S., Lee, J. H., Oh, K., Lee, E., Han, B., Park, K.-Y., Suh, J. M., Min, J., Chi, S., Lee, S. C., et al. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154173 · Cited by 36
Self-citationCancer metabolomics in basic science perspective
Kwon, H. N., Oh, S., Jin, X., An, Y., & Park, S. (2015) · Archives of Pharmacal Research · doi:10.1007/s12272-015-0552-4 · Cited by 34
Li, A. M., & Ye, J. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-062822-120857 · Cited by 36
Huse, J. T., Wallace, M., Aldape, K., Berger, M. S., Bettegowda, C., Brat, D. J., Cahill, D. P., Cloughesy, T. F., Haas-Kogan, D. A., Marra, M. A., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not229 · Cited by 32
Ricoult, S. J. H., Dibble, C. C., Asara, J. M., & Manning, B. D. (2016) · Molecular and Cellular Biology · doi:10.1128/mcb.00163-16 · Cited by 31
Radiomics, Metabolic, and Molecular MRI for Brain Tumors
Kickingereder, P., & Andronesi, O. C. (2018) · Seminars in Neurology · doi:10.1055/s-0037-1618600 · Cited by 32
Bai, X., Zhang, H., Zhou, Y., Nagaoka, K., Meng, J., Ji, C., Liu, D., Dong, X., Cao, K. Y., Mulla, J., et al. (2020) · Hepatology · doi:10.1002/hep.31486 · Cited by 31
Metadata
- Authors
- Koivunen, P., Lee, S., Duncan, C. G., Lopez, G., Lu, G., Ramkissoon, S., Losman, J. A., Joensuu, P., Bergmann, U., Gross, S., Travins, J., Weiss, S., Looper, R., Ligon, K. L., Verhaak, R. G. W., Yan, H., & Kaelin Jr, W. G.
- Affiliations
- University of Oulu (FI)
- Brigham and Women's Hospital (US)
- Duke University (US)
- Agios Pharmaceuticals (United States) (US)
- University of Calgary (CA)
- University of Utah (US)
- The University of Texas MD Anderson Cancer Center (US)
- ORCID
- Venue
- Nature
- Published
- 2012-02-15
- Volume
- 483
- Issue
- 7390
- Pages
- 484-488
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3656605
- OpenAlex
- W2142898716
- Cited by
- 727
- References
- 41
- Citations by year
- 2026: 17 · 2025: 31 · 2024: 38 · 2023: 32 · 2022: 35 · 2021: 44 · 2020: 56 · 2019: 52 · 2018: 66 · 2017: 63 · 2016: 61 · 2015: 57 · 2014: 70 · 2013: 59 · 2012: 43
- FWCI
- 24.42
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Cancer Institute (R01CA068490, R01CA140316)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- R-enantiomer, IDH1 mutation, IDH2 mutation, hypoxia-inducible factor, glioma, astrocyte proliferation, oncometabolites, cancer metabolism, histone demethylation, DNA hypermethylation, CpG island methylator phenotype
- MeSH terms
- Astrocytes, Cell Line, Cell Transformation, Neoplastic, Enzyme Activation, Glioma, Glutarates, Humans, Isocitrate Dehydrogenase, Nuclear Proteins, Oncogenes, Procollagen-Proline Dioxygenase, Cell Line, Tumor, Cell Proliferation, Dioxygenases, Hypoxia-Inducible Factor 1, Hypoxia-Inducible Factor-Proline Dioxygenases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.